Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 240Rectal Neoplasms 93Colonic Neoplasms 91Pancreatic Neoplasms 87Stomach Neoplasms 68Neoplasm Metastasis 47Esophageal Neoplasms 41Neoplasms 36Small Cell Lung Carcinoma 29Lung Neoplasms 29Neuroblastoma 28Glioblastoma 28Glioma 27Brain Neoplasms 26Carcinoma, Non-Small-Cell Lung 22Adenocarcinoma Of Esophagus 20Gliosarcoma 19Breast Neoplasms 18Astrocytoma 18Esophageal Squamous Cell Carcinoma 17Central Nervous System Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Oligodendroglioma 13Adenocarcinoma 13Rhabdomyosarcoma 10Gastrointestinal Neoplasms 10Biliary Tract Neoplasms 10Sarcoma 9Gallbladder Neoplasms 9Cholangiocarcinoma 9

Interventions

Bevacizumab 2trifluridine tipiracil drug combination 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × mCRC × Irinotecan × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡